BR112017017608A2 - methods for treating schizophrenia or a symptom of schizophrenia, to prevent a schizophrenic relapse and to maintain the effect of iloperidone for schizophrenia. - Google Patents
methods for treating schizophrenia or a symptom of schizophrenia, to prevent a schizophrenic relapse and to maintain the effect of iloperidone for schizophrenia.Info
- Publication number
- BR112017017608A2 BR112017017608A2 BR112017017608-4A BR112017017608A BR112017017608A2 BR 112017017608 A2 BR112017017608 A2 BR 112017017608A2 BR 112017017608 A BR112017017608 A BR 112017017608A BR 112017017608 A2 BR112017017608 A2 BR 112017017608A2
- Authority
- BR
- Brazil
- Prior art keywords
- iloperidone
- daily dose
- schizophrenia
- relapse
- individual
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562117173P | 2015-02-17 | 2015-02-17 | |
| US62117173 | 2015-02-17 | ||
| US201562172436P | 2015-06-08 | 2015-06-08 | |
| US62/172436 | 2015-06-08 | ||
| PCT/US2016/018316 WO2016134049A1 (en) | 2015-02-17 | 2016-02-17 | Iloperidone for the treatment of schizophrenia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017017608A2 true BR112017017608A2 (en) | 2018-05-08 |
Family
ID=55532275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017017608-4A BR112017017608A2 (en) | 2015-02-17 | 2016-02-17 | methods for treating schizophrenia or a symptom of schizophrenia, to prevent a schizophrenic relapse and to maintain the effect of iloperidone for schizophrenia. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10441580B2 (enExample) |
| EP (1) | EP3258935B1 (enExample) |
| JP (1) | JP6885649B2 (enExample) |
| KR (1) | KR102870956B1 (enExample) |
| CN (2) | CN116211857A (enExample) |
| BR (1) | BR112017017608A2 (enExample) |
| CA (1) | CA2976383C (enExample) |
| ES (1) | ES2870498T3 (enExample) |
| WO (1) | WO2016134049A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11214827B2 (en) * | 2018-08-30 | 2022-01-04 | Vanda Pharmaceuticals Inc. | Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone |
| JP2026504721A (ja) * | 2022-12-19 | 2026-02-09 | バンダ・ファーマシューティカルズ・インコーポレイテッド | 双極ｉ型障害及び統合失調症の治療のためのイロペリドンの投与レジメン |
| WO2024249952A1 (en) | 2023-06-02 | 2024-12-05 | Vanda Pharmaceuticals Inc. | Method of treatment with iloperidone |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2305656T3 (da) | 2001-08-31 | 2013-02-11 | Novartis Ag | Optiske isomerer of en iloperidonmetabolit |
| ES2358416T3 (es) | 2001-10-30 | 2011-05-10 | Novartis Ag | Formulaciones de liberación prolongada de iloperidona y polímero en forma de estrella. |
| GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
| US20100063093A1 (en) * | 2007-03-28 | 2010-03-11 | Curt Wolfgang | Methods for the administration of iloperidone |
| CA3113166A1 (en) * | 2004-09-30 | 2006-04-13 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
| WO2009036056A1 (en) | 2007-09-10 | 2009-03-19 | Vanda Pharmaceuticals, Inc. | Antipsychotic treatment based on snp genotype |
| KR20100099292A (ko) * | 2007-12-19 | 2010-09-10 | 얀센 파마슈티카 엔.브이. | 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법 |
| CA2760474C (en) * | 2009-05-15 | 2020-08-18 | Vanda Pharmaceuticals Inc. | Antipsychotic treatment based on drd2 or ankk1 snp genotype |
| EP2785347A1 (en) * | 2011-12-02 | 2014-10-08 | Dainippon Sumitomo Pharma Co., Ltd. | Lurasidone novel dosage regimens and use thereof for the treatment, prevention, and/or management of at least one cns disorder |
| IN2014DN08495A (enExample) | 2012-03-14 | 2015-05-08 | Vanda Pharmaceuticals Inc | |
| IL275725B (en) * | 2012-08-21 | 2022-08-01 | Sage Therapeutics Inc | Treatment methods for epilepsy and status epilepticus |
-
2016
- 2016-02-17 ES ES16710038T patent/ES2870498T3/es active Active
- 2016-02-17 CN CN202310398029.9A patent/CN116211857A/zh active Pending
- 2016-02-17 EP EP16710038.7A patent/EP3258935B1/en active Active
- 2016-02-17 KR KR1020177026225A patent/KR102870956B1/ko active Active
- 2016-02-17 US US15/549,820 patent/US10441580B2/en active Active
- 2016-02-17 WO PCT/US2016/018316 patent/WO2016134049A1/en not_active Ceased
- 2016-02-17 CA CA2976383A patent/CA2976383C/en active Active
- 2016-02-17 CN CN201680010479.4A patent/CN107249586A/zh active Pending
- 2016-02-17 BR BR112017017608-4A patent/BR112017017608A2/en not_active Application Discontinuation
- 2016-02-17 JP JP2017543816A patent/JP6885649B2/ja active Active
-
2019
- 2019-09-06 US US16/562,548 patent/US10987346B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HK1248551A1 (zh) | 2018-10-19 |
| US20180021324A1 (en) | 2018-01-25 |
| JP2018505901A (ja) | 2018-03-01 |
| CN116211857A (zh) | 2023-06-06 |
| CA2976383C (en) | 2023-05-23 |
| ES2870498T3 (es) | 2021-10-27 |
| EP3258935A1 (en) | 2017-12-27 |
| CN107249586A (zh) | 2017-10-13 |
| US10441580B2 (en) | 2019-10-15 |
| EP3258935B1 (en) | 2021-04-07 |
| JP6885649B2 (ja) | 2021-06-16 |
| WO2016134049A1 (en) | 2016-08-25 |
| CA2976383A1 (en) | 2016-08-25 |
| KR102870956B1 (ko) | 2025-10-16 |
| US20190388412A1 (en) | 2019-12-26 |
| KR20170118830A (ko) | 2017-10-25 |
| US10987346B2 (en) | 2021-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zajecka et al. | A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder | |
| Bowden et al. | Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. | |
| EP4397317A2 (en) | Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine | |
| US10987346B2 (en) | Iloperidone for the treatment of schizophrenia | |
| US20250099466A1 (en) | Milvexian for prevention and treatment of thromboembolic disorders | |
| Shiovitz et al. | A randomized, double-blind, placebo-controlled trial of the efficacy and safety of levomilnacipran ER 40-120mg/day for prevention of relapse in patients with major depressive disorder | |
| JP2024050575A (ja) | Ｌ－４－クロロキヌレニンの治療的使用 | |
| US10722486B2 (en) | Method of treating patients with a factor Xa inhibitor, aspirin, and verapamil | |
| EA028060B1 (ru) | Комбинированная терапия бокового амиотрофического склероза | |
| JP2015522077A5 (enExample) | ||
| Bennett et al. | The role of ondansetron in the treatment of schizophrenia | |
| TWI888340B (zh) | 用於預防或治療貓之全身性疾病之血管收縮素ii受體拮抗劑 | |
| HK1248551B (en) | Iloperidone for the treatment of schizophrenia | |
| Doyle et al. | Psychotropic medications, associated QTc prolongation, and sudden cardiac death: a review for clinicians | |
| Farmer et al. | Pharmacological intervention for disruptive behaviors in intellectual and developmental disabilities: the glass is half full | |
| JP2018507216A (ja) | 多発性骨髄腫に対するパノビノスタット投与量 | |
| Rajiv et al. | First-line Therapy in Status Epilepticus | |
| CN108938645A (zh) | 一种抗精神病药物组合物 | |
| US20050124601A1 (en) | Methods for the treatment of bipolar disorder using carbamazepine | |
| Dubovsky et al. | P. 3. c. 055 Asenapine: short-term tolerability, safety, and pharmacokinetic profile in older patients with psychosis | |
| US20160051560A1 (en) | Treatments involving eslicarbazepine or eslicarbazepine acetate | |
| US20060094709A1 (en) | Methods for the treatment of bipolar disorder using carbamazepine | |
| Correll et al. | The Effects of Valbenazine in Participants with Tardive Dyskinesia | |
| Willis et al. | P. 3. c. 044 Antipsychotic polypharmacy in a community psychiatric clinic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |